Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Warner Chilcott, a specialty pharmaceutical company, has announced that one of its subsidiaries and Mayne Pharma International, a subsidiary of Hospira, have filed a lawsuit against Sandoz in the District Court of New Jersey for infringement of Mayne's US patent which covers Doryx, a tetracycline-class oral antibiotic.
Subscribe to our email newsletter
The lawsuit is in response to the submission of an abbreviated new drug application to the FDA by Sandoz requesting approval to manufacture and sell generic versions of Doryx 100 and 75mg delayed-release tablets prior to the expiration in 2022 of the patent. Warner Chilcott and Mayne intend to vigorously defend the patent and pursue their legal rights.
Warner Chilcott markets and sells Doryx delayed-release tablets in 150, 100 and 75mg strengths under a licensing agreement with Mayne. Warner Chilcott previously announced the filing of similar lawsuits against each of Mutual Pharmaceutical Company, Mylan Pharmaceuticals and Impax Laboratories on December 23, 2008.